Roivant Sciences (ROIV) President Sukhatme Sells $17M of Stock
Roivant Sciences' President & CIO, Mayukh Sukhatme, sold shares worth $17.07 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Mayukh Sukhatme, President & CIO at Roivant Sciences Ltd. ($ROIV), sold 500,000 shares at an average price of $34.13, worth about $17.07 million, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $ROIV is up 3.3% after 1 week, up 2.1% after 1 month and down 1.4% to date (from the $34.02 close on Jun 25, 2026).
ROIV
Roivant Sciences Ltd.
Key Points
- Mayukh Sukhatme, President & CIO of Roivant Sciences, sold 500,000 shares for $17.07 million on June 25, 2026.
- Roivant Sciences Ltd. trades on NasdaqGS with a market cap of approximately $24.51 billion and a 52-week high of $34.68.
- Analysts maintain a strong buy consensus for Roivant, with a target mean price of $39.04.
Get $ROIV trade alerts by text
We text you when insiders, Congress or big funds trade $ROIV. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Roivant Sciences Ltd. alert may contain errors. Disclosures
On June 25, 2026, Mayukh Sukhatme, the President and Chief Investment Officer of Roivant Sciences Ltd. (NasdaqGS: ROIV), sold 500,000 shares of the company. The transaction was valued at approximately $17.07 million, with an average price of $34.13 per share. This sale was not part of a pre-arranged trading plan.
Insider Buying and Selling at Roivant Sciences Ltd.
Mayukh Sukhatme, as President & CIO, made several transactions around this period. On June 26, 2026, he again sold 500,000 shares at an average price of $34.08. These sales follow a pattern of significant insider activity, although they were not planned trades.
Roivant Sciences Ltd. Stock Up 2.0%
Shares of Roivant Sciences Ltd. traded near $34.07 on Tuesday. The company, which operates in the biotechnology sector, boasts a market capitalization of about $24.51 billion. Although currently not profitable, Roivant holds a forward P/E ratio of -21.85. The stock's 52-week range is from $10.71 to $34.68, and it has a beta of 1.137, indicating moderate volatility. The company's liquidity appears strong with a current ratio of 18.37 and a quick ratio of 18.00.
Analysts Set New Price Targets
Analysts remain bullish on Roivant Sciences. On May 26, 2026, Guggenheim maintained a buy rating with a price target of $36. Citigroup and TD Cowen also reaffirmed their buy ratings with targets of $42 and $41, respectively, on May 21, 2026. The consensus among analysts is a strong buy, with an average target price of $39.04 based on 12 opinions.
About Roivant Sciences
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom. It focuses on developing and commercializing innovative medicines and technologies. The company is involved in several therapeutic areas, including autoimmune diseases and pulmonary hypertension. Roivant also offers advanced delivery platforms, such as lipid nanoparticle and ligand conjugate technologies. Founded in 2014, the company employs 721 people and is led by CEO Matthew Gline.
Bottom Line
The recent insider sale by Mayukh Sukhatme highlights significant activity within Roivant Sciences. Investors often track such moves for insights into company leadership's confidence. It's important to note that these transactions are disclosed after the fact and may not reflect ongoing sentiment. Roivant's stock remains a focus for analysts, with a strong buy consensus suggesting optimism about its future prospects.
Related Filing Alerts
Source: Mayukh Sukhatme's Form 4 filing on $ROIV (Jun 25, 2026). Find the original filing: ROIV Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts